News Archives


In 2012, Sanofi Pasteur Toronto embraced Sanofi’s Environmental Sustainability goals and made a commitment to develop initiatives to significantly reduce its environmental footprint. This report highlights these efforts and results for 2012, and summarizes plans for 2013.


Model, snowboarder and meningitis survivor Amy Purdy feels lucky: find out why.


Meningitis is a serious illness which can cause death in less than 24 hours. Active immunization is the best protection.

Since 1974, Sanofi Pasteur has been present in the fight against meningitis with the Meningo A+C vaccines, which continue to play a vital role in the prevention of meningococcal diseases in Africa and other regions.

From the 1981 launch of Menomune® onwards, patients were able to benefit from our first tetravalent polysaccharide vaccine against serogroups A, C, Y and W-135. The range was enlarged in 2005 with the introduction of Menactra® which is licensed in more than 40 countries.

Today, Menactra® is the only tetravalent conjugate vaccine indicated for children (from nine months old).


Coquitlam girl, 17, investigated how genetic mutations naturally help some HIV patients escape symptoms


Chicago, IL April 23, 2013 - Selin Jessa of Coquitlam, B.C. has been awarded the fourth place, $1,000 prize in this year’s International BioGENEius Challenge science competition for high school students at the Biotechnology Industry Association’s annual conference in Chicago. 

The 17-year-old Jessa competed against fellow Canadian Arjun Nair of Calgary, 10 finalists from the US BioGENEius Challenge and two students from the Western Australia version of the competition. Jessa and Nair won the opportunity to compete at BIO by taking the second and first prizes respectively in the national competition of the Sanofi BioGENEius Challenge Canada earlier this month.

Her research involved genetic variations found among a rare few HIV-infected patients, known as "elite controllers”, whose immune systems naturally control common symptoms of the virus. The immune responses of elite controllers are so effective that HIV can only survive through mutations that compromise its ability to replicate. Selin engineered a mutant version of a specific HIV protein, an important step in identifying these viral mutations that may help design vaccines or other HIV therapies.  Project description:

This latest award brings the Grade 12 student’s cash prizes to a total of $7,500 from the provincial, national and international BioGENEius Challenge competitions. She attends the Dr. Charles Best Secondary School in Coquitlam and carried out her research at Simon Fraser University in Vancouver.

Launched at BIO’s first international conference in Toronto in 1994 and celebrating 20 years of competitions, the BioGENEius Challenge provides young scientists with access to professional labs and academic mentors, encouraging them to pursue future studies and careers in the fast-growing biotechnology sector.

Among the judges in this year’s international competition was Robert Merson, a participant in that first competition and now a consultant in the biotechnology industry. Also attending BIO was Ted Paranjothy of Manitoba, who won the provincial, Canadian and international BioGENEius Challenges in 2007.  Ted was the guest speaker at the luncheon hosted by Gowlings, a Canadian legal firm, and also spoke with the American, Canadian and Australian BioGENEius competitors about his academic and work career since winning all three awards. 

Both the US national and international BioGENEius Challenge competitions are organized by the Washington-based Biotechnology Institute, the national organization dedicated to biotechnology education, and sponsored by Sanofi Pasteur, the vaccines division of Sanofi; and Janssen.

Further support for the BioGENEius Challenge is provided by International Supporters: The Astellas Foundation, BIO, Genentech and MedImmune; and U.S. National Supporters: Acorda Therapeutics, The Allergan Foundation and Sangamo BioSciences.


About the Sanofi BioGENEius Challenge Canada (SBCC)

The Sanofi BioGENEius Challenge Canada (SBCC) is a national, biotechnology research competition that encourages high school and CEGEP students to pursue future studies and careers in the exciting field of biotechnology. The initiative is sponsored by Sanofi Pasteur Limited, Sanofi Canada, the National Research Council Canada/ Conseil national de recherches Canada (NRC-CNRC), Canadian Institutes of Health Research/Instituts de recherche en santé du Canada (CIHR-IRSC), York University, Genome Canada and the Government of Canada’s Youth Awareness Program. Canada’s respected Sanofi BioGENEius Challenge Canada has inspired counterpart competitions in the USA and Australia.

Media Contacts:


Jason LeSAGE


604.602.5227; 604.910.6881



Tel: 416-878-8712; 416-538-8712 


Whether you are a parent, a young adult or a senior, talk to your doctor, nurse, pharmacist or local public health office about being up to date on your immunizations. provides informative resources on immunization.


30-year Industry Veteran Advocate for Advancing Science, Innovation and Canadian Competitiveness


Toronto, Ontario – April 11, 2013 – Mark Lievonen, President of Sanofi Pasteur Limited, the Canadian vaccine division of the Sanofi Group, has been inducted into the 2013 Canadian Marketing Healthcare Hall of Fame Award, in recognition of his outstanding contributions to the healthcare industry.

The Canadian Healthcare Marketing Hall of Fame was established in 1988 to honour lifetime achievement in healthcare marketing. This award is the highlight of the annual National Pharmaceutical Congress organized by the Chronicle Companies.

“Through a career spanning over 30 years, Mark Lievonen has made a lasting impact on the industry and served as a source of inspiration to others,” said Mitchell Shannon, Publisher, The Chronicle Newspapers, which sponsors the award. “The judging committee was impressed by Mr. Lievonen’s extraordinary dedication and commitment to the profession. Under his leadership, Sanofi Pasteur has become a billion dollar enterprise in Canada, and is a symbol of Canadian talent, innovation and R&D excellence.”

Lievonen is an active member in the life sciences sector. He is a member of several organizations, notably: Director, Oncolytics Biotech Inc.; Vice-Chair, Ontario Institute for Cancer Research; First Vice-Chair, Rx&D; Chair, Markham Stouffville Hospital Foundation; Director, Public Policy Forum; Governor, York University; Director, BIOTECanada; Director, Markham Stouffville Hospital; and Director, York University Development Corporation. 

“I am truly honoured to receive this recognition on behalf of Sanofi Pasteur, my colleagues and my community, and I am proud that we have been able to play a small part in preventing disease and saving lives in Canada and all around the world,” says Mark Lievonen.  “I am energized by the work we do, inspired by my passionate colleagues and humbled by our role in impacting human lives each and every day.”

Lievonen has been the recipient of the Queen’s Golden Jubilee Medallion (2002), the Chevalier de l'Ordre National de Mérite by the Government of France (2007), Fellow, Ontario Institute of Chartered Accountants (2009) and received the Queen’s Diamond Jubilee Medallion (2012). Twenty years ago, Lievonen also spearheaded Canada’s only mentored science competition, the Sanofi BioGENEius Challenge Canada (SBCC), to foster biotechnology talent in Canada among high school students.  For a complete biography click here.

Mark Lievonen joined Sanofi Pasteur Canada in 1983 and has been the President since 1999. For almost 100 years, Sanofi Pasteur has been at the forefront of innovation in vaccine R&D, and has made more than $600 million in capital expenditures since 2000.  The company manufactures over 50 million doses of vaccines in Canada for both domestic and international markets, and is the only manufacturer of 5-component acellular pertussis combination vaccines, which was launched in Canada as Pentacel® in 1997.  Sanofi Pasteur has a broad vaccine portfolio in Canada, including Pediacel®, Menactra®, Adacel®, Intanza®, Vaxigrip®, ViVaxim®, Typhim Vi® and YF-Vax®.

Nominations for the 2013 selection of honorees were solicited during the past months from the publication’s readers.  Since 1988, 95 healthcare visionaries, original thinkers and leaders have been honoured with this prestigious distinction. Numerous submissions were received and a committee consisting of the publications' editors and an ad hoc group of industry advisors undertook the difficult task of determining from among the Nominees the candidates who best exemplified the qualities described above, based on the information submitted by the individual(s) making the nomination.


About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: or


Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.




Sanofi Pasteur                                                                       CASACOM    

Nancy Simpson                                                                       Kara Latta

T. 416-667-2955                                                                     T. 416-944-2145